Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11275
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elsalys Biotech SA (Elsalys Biotech) is a pharmaceutical company that develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases. The company’s pipeline programs include anti-CD160, for macular degeneration or certain retinopathies; anti-CD160, for solid tumors and blood cancer; anti-Tyro3, for solid tumors; and anti-S100b, for idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. It also develops Leukotac, an immunotherapy antibody developed for the treatment of orphan disease with very poor prognosis: steroid-resistant acute graft versus host disease. Elsalys Biotech’s specialization spans from target sourcing to the pre-industrial production of drug candidates. The company works in collaboration with academic and other industry partners to conduct programs, clinical evaluation of antibody candidates and to develop immune-based therapies. Elsalys Biotech is headquartered in Lyon, France.

Elsalys Biotech SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
Venture Financing 12
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Licensing Agreements 15
Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15
Elsalys Biotech Enters into Licensing Agreement with Transgene 16
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17
Equity Offering 18
Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18
Acquisition 19
Transgene Acquires 37% Stake in ElsaLys Biotech 19
Elsalys Biotech SA – Key Competitors 20
Elsalys Biotech SA – Key Employees 21
Elsalys Biotech SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Jan 30, 2017: Elsalys Biotech expands its team to strengthen its strategy and the development of its programs 23
Product News 25
04/05/2018: Elsalys Biotech: LEUKOTAC takes next step in paediatric acute steroid-resistant GvHD 25
03/15/2018: EUKOTAC at the 44th Congress of the European Society for Blood and Marrow Transplantation (EBMT) 26
Clinical Trials 27
Jul 18, 2017: ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Key Facts 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Deals By Therapy Area, 2012 to YTD 2018 8
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10
ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11
ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 13
Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15
Elsalys Biotech Enters into Licensing Agreement with Transgene 16
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17
Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18
Transgene Acquires 37% Stake in ElsaLys Biotech 19
Elsalys Biotech SA, Key Competitors 20
Elsalys Biotech SA, Key Employees 21
Elsalys Biotech SA, Other Locations 22

List of Figures
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Schneider National Inc (SNDR):企業の財務・戦略的SWOT分析
    Schneider National Inc (SNDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Allianz Group:企業の戦略・SWOT・財務情報
    Allianz Group - Strategy, SWOT and Corporate Finance Report Summary Allianz Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Humanigen Inc(Humanigen) formerly known as KaloBios Pharmaceuticals Inc, is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasiti …
  • Petrofac Ltd (PFC):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrofac Limited (Petrofac) is an oilfield services company that provides integrated services to production and processing industries. It designs and builds oil and gas facilities; operates, maintains and manages facilities on behalf of its customers and trains personnel. It also develops an …
  • Zafgen Inc (ZFGN):製薬・医療:M&Aディール及び事業提携情報
    Summary Zafgen Inc (Zafgen) is a clinical-stage biopharmaceutical company that develops transformative therapies for patients affected by a range of metabolic diseases. Its pipeline product portfolio includes ZGN-1061, a small molecule MetAP2 inhibitor being developed for patients with type 2 diabet …
  • Shamrock Foods Company:企業の戦略的SWOT分析
    Shamrock Foods Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • T&D Holdings, Inc.:企業の戦略・SWOT・財務情報
    T&D Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary T&D Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Worthington Industries Inc:企業の戦略・SWOT・財務分析
    Worthington Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Worthington Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • LKQ Corporation:企業の戦略・SWOT・財務情報
    LKQ Corporation - Strategy, SWOT and Corporate Finance Report Summary LKQ Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Suzlon Energy Ltd (SUZLON):電力:M&Aディール及び事業提携情報
    Summary Suzlon Energy Ltd (Suzlon) is a provider of renewable energy solutions. It offers total solutions package that covers the entire wind energy projects scope. The company provides complete turnkey solutions from design to lifecycle asset management. Suzlon also generates electricity; and sells …
  • Daxor Corp (DXR):企業の財務・戦略的SWOT分析
    Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Geron Corp (GERN):企業の財務・戦略的SWOT分析
    Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Yonsei University:製薬・医療:M&Aディール及び事業提携情報
    Summary Yonsei University (Yonsei) is an educational service provider that offers training and research services. The university offers graduation programs in various areas such as applied statistics, architectural engineering, Asian studies, astronomy, atmospheric sciences, biochemistry, bio conver …
  • InterGen:企業の戦略的SWOT分析
    InterGen - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • MC Mining Ltd:企業のM&A・事業提携・投資動向
    MC Mining Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MC Mining Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • ManpowerGroup, Inc.:企業の戦略・SWOT・財務情報
    ManpowerGroup, Inc. - Strategy, SWOT and Corporate Finance Report Summary ManpowerGroup, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Mexco Energy Corp:企業の財務・戦略的SWOT分析
    Summary Mexco Energy Corp (Mexco Energy) is an oil and gas company that offers exploration, acquisition, production, and development of crude oil, natural gas, condensate liquids, and natural gas liquids. The company acquires producing and non-producing oil and gas leases from landowners and leaseho …
  • Toyo Tire & Rubber Co Ltd (5105):企業の財務・戦略的SWOT分析
    Toyo Tire & Rubber Co Ltd (5105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Pinnacle Investment Management Group Ltd (PNI):企業の財務・戦略的SWOT分析
    Pinnacle Investment Management Group Ltd (PNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆